Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in Dementia With Lewy Bodies
NCT03888222Phase 2Completed
- Sponsor
- Georgetown University
- Start
- Apr 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) comparing Placebo with 100 mg of Bosutinib (2 arms). Primary endpoint: Safety and Tolerability Go/NoGo (25% Discontinuations) at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
bosutinib
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT03888222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888222.